HK1208620A1 - Pharmaceutical composition of entecavir and process of manufacturing - Google Patents

Pharmaceutical composition of entecavir and process of manufacturing Download PDF

Info

Publication number
HK1208620A1
HK1208620A1 HK15109146.7A HK15109146A HK1208620A1 HK 1208620 A1 HK1208620 A1 HK 1208620A1 HK 15109146 A HK15109146 A HK 15109146A HK 1208620 A1 HK1208620 A1 HK 1208620A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
adhesive
entecavir
manufacturing
free
Prior art date
Application number
HK15109146.7A
Other languages
English (en)
Chinese (zh)
Inventor
Mathew Philip
Naresh Talwar
Original Assignee
Pharmascience Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc. filed Critical Pharmascience Inc.
Publication of HK1208620A1 publication Critical patent/HK1208620A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15109146.7A 2012-05-31 2013-05-28 Pharmaceutical composition of entecavir and process of manufacturing HK1208620A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2779052 CA2779052A1 (en) 2012-05-31 2012-05-31 Pharmaceutical composition of entecavir and process of manufacturing
CA2,779,052 2012-05-31
PCT/CA2013/000517 WO2013177672A1 (en) 2012-05-31 2013-05-28 Pharmaceutical composition of entecavir and process of manufacturing

Publications (1)

Publication Number Publication Date
HK1208620A1 true HK1208620A1 (en) 2016-03-11

Family

ID=49672225

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109146.7A HK1208620A1 (en) 2012-05-31 2013-05-28 Pharmaceutical composition of entecavir and process of manufacturing

Country Status (9)

Country Link
US (2) US20150110869A1 (enExample)
EP (1) EP2854773B1 (enExample)
JP (1) JP6320371B2 (enExample)
KR (1) KR20150015500A (enExample)
CN (1) CN104363896A (enExample)
CA (2) CA2779052A1 (enExample)
HK (1) HK1208620A1 (enExample)
IN (1) IN2014MN02487A (enExample)
WO (1) WO2013177672A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3158998A4 (en) 2014-06-20 2018-02-14 CTC Bio, Inc. Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
CN104473896B (zh) * 2014-12-01 2017-04-19 东莞市金美济药业有限公司 一种快速崩解的拉米夫定片及其制备工艺
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
EP3606523A1 (en) * 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
CN109550020A (zh) * 2019-02-14 2019-04-02 任连智 一种治疗乙肝大小三阳的药物制剂及制备方法
CN110354129A (zh) * 2019-08-19 2019-10-22 苏州扬厉医药科技有限公司 一种治疗乙肝病毒的新药药物组合及制备方法
AU2022289906A1 (en) * 2021-06-07 2023-11-09 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229775A1 (en) * 2000-02-29 2001-09-12 Bristol-Myers Squibb Company Low dose entecavir formulation and use
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7905852B2 (en) * 2006-05-16 2011-03-15 Barbara Jennings-Spring Skin-contacting-adhesive free dressing
US20070281000A1 (en) * 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
WO2009106954A1 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable dosage forms of lamivudine and tenofovir
WO2009106960A2 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011076412A1 (de) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Orale darreichungsform umfassend entecavir
NZ610729A (en) * 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
EP2508172A1 (en) * 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
EP2780001A4 (en) * 2011-11-14 2015-10-28 Hetero Research Foundation SOLID ORAL ENTECAVIR COMPOSITIONS WITH FAST RELEASE
WO2013114389A1 (en) * 2011-12-21 2013-08-08 Mylan Laboratories Limited. Process for preparing solid oral formulations comprising low dose of entecavir

Also Published As

Publication number Publication date
JP6320371B2 (ja) 2018-05-09
EP2854773B1 (en) 2020-05-06
IN2014MN02487A (enExample) 2015-07-17
US20190076366A1 (en) 2019-03-14
EP2854773A1 (en) 2015-04-08
CA2874779C (en) 2019-03-05
US20150110869A1 (en) 2015-04-23
WO2013177672A1 (en) 2013-12-05
CA2779052A1 (en) 2013-11-30
KR20150015500A (ko) 2015-02-10
CA2874779A1 (en) 2013-12-05
JP2015521191A (ja) 2015-07-27
EP2854773A4 (en) 2016-01-27
CN104363896A (zh) 2015-02-18

Similar Documents

Publication Publication Date Title
IN2014MN02487A (enExample)
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
WO2011158039A8 (en) Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2009110005A3 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
PH12014500853A1 (en) Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2013022243A3 (ko) 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
WO2014008248A3 (en) Compositions and methods for treating and inhibiting viral infections
MX2013007661A (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
WO2010003472A3 (de) Lutschzusammensetzung zur behandlung von entzündlichen erkrankungen des mund- und rachenraums
WO2007003330A3 (de) Pharmazeutische darreichungsformen enthaltend eine wirkstoffkombination von nifedipin und/oder nisoldipin und einem angiotensin-ii antagonisten
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2013028615A3 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
HK1218861A1 (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈可分散的片剂形式的抗结核病的稳定的药物组合物及其制备方法
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
WO2012077968A3 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
HUE071451T2 (hu) Vegyület, gyógyászatilag elfogadható sója vagy optikai izomere, eljárás elõállítására és hatóanyagként azt tartalmazó, vírusos betegség megelõzésére vagy kezelésére szolgáló gyógyászati készítmény